UNSPSC 51171969: Tuvatidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C10H17N9O2S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TWN203TLYT, chemically known as guanidine, (4-(((2-((5-amino-4-methyl-4h-1,2,4,6-thiatriazin-3-yl)amino)ethyl)thio)methyl)-2-thiazolyl)-, s,s-dioxide but generally known as tuvatidine, which bears US NIH Compound Identifier 65826. European Medicines Agency schedules Tuvatidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11368MIG.

UNSPSC 51171969 Tuvatidine is a Commodity-tier code that maps poorly to actual state and local procurement activity. The recent opportunities tagged under this code involve offender drug testing services, direct-to-manufacturer pharmacy initiatives, and generic pharmaceutical sourcing through cooperative purchasing — none of which align with tuvatidine, a pharmaceutical compound used primarily in oncology and infectious-disease treatment. The mismatch suggests either miscoding by the issuing bodies or a divergence between the UNSPSC taxonomy and the specific procurement descriptions in the source materials. The code shows little relevant recent activity in the state and local market as typically understood.

The three opportunities on record span Texas (Collin County Community Supervision and Corrections Department and Texas Health and Human Services Commission) and Minnesota (through MMCAP, a multistate cooperative purchasing alliance serving state and local government facilities across participating jurisdictions including Oregon). Collin County issued an RFP (2026-327) for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000; Texas HHS issued an RFI for direct-to-manufacturer prescription programs with no award value specified; and Minnesota's MMCAP issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026. None of these solicitations explicitly demand or reference tuvatidine, indicating that the code assignment does not reflect the actual scope of goods or services being procured.